In Russia, proved the effectiveness of Mefloquine against coronavirus
According to the Federal Biomedical Agency of Russia (FMBA) Doctors have proven the antiviral activity of the drug mefloquine against the pathogen COVID-19.
The study of the clinical effects of the drug is carried out as part of a comparative study at three centers of FMBA of Russia – SSC FMBC them. A.I. Burnazyan FMBA of Russia, FNCC FMBA of Russia, FCTC VMT FMBA of Russia, ”said Veronika Skvortsova.
According to the head of FMBA Veronika Skvortsova, mefloquine completely blocked the development of the cytopathic effect of the SARS-CoV-2 virus in cell culture at a concentration of two micrograms per liter.
“Such a plasma concentration is achieved after taking the drug in therapeutic doses authorized for use in humans,” she said.
The studies were carried out by the Pharmaceutical Defense Research and Production Center with the participation of the 48th Central Research Institute of the Ministry of Defense, the press service specified.
On the eve of the Ministry of Health issued a new, fifth edition of the recommendations on the prevention and treatment of coronavirus infection.
In particular, the list of drugs included chloroquine, hydroxychloroquine, lopinavir plus ritonavir, azithromycin (in combination with hydroxychloroquine) and interferon preparations. Mefloquine, as well as hydroxychloroquine, is recommended for those who have been in contact with infected people.
Three more drugs – umifenovir, remdesivir and favipiravir – are at the stage of clinical trials.